Clinical associations of serum interleukin-17 in systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 15, Issue 4, 2013, Pages

  Vincent, Fabien B ^a   Northcott, Melissa ^a   Hoi, Alberta ^a   Mackay, Fabienne ^a   Morand, Eric F ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Autoimmunity; B cell activating factor of the tumour necrosis factor (TNF) family (BAFF); interleukin 17; interleukin 6; macrophage migration inhibitory factor (MIF); systemic lupus erythematosus (SLE); T helper 17 (Th17)

Indexed keywords

B CELL ACTIVATING FACTOR; C REACTIVE PROTEIN; CREATININE; INTERLEUKIN 17; INTERLEUKIN 6; MIGRATION INHIBITION FACTOR; PREDNISONE; CYTOKINE; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD LEVEL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; CROSS-SECTIONAL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84882529537     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4277     Document Type: Article

References (52)

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011, 365:2110-2121. 10.1056/NEJMra1100359, 22129255.
2. Vincent FB, Morand EF, Mackay F. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol Cell Biol 2012, 90:293-303. 10.1038/icb.2011.111, 22231653.
3. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141. 10.1038/ni1261, 1618871, 16200068.
4. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132. 10.1038/ni1254, 16200070.
5. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970. 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E, 10323452.
6. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, Takabayashi K, Iwamoto I. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000, 43:2455-2463. 10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K, 11083268.
7. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8:500-508. 10.1038/nm0502-500, 11984595.
8. Nalbandian A, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009, 157:209-215. 10.1111/j.1365-2249.2009.03944.x, 2730846, 19604260.
9. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, Yi J, Guentert T, Tousson A, Stanus AL, Le TV, Lorenz RG, Xu H, Kolls JK, Carter RH, Chaplin DD, Williams RW, Mountz JD. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008, 9:166-175.
10. Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, Wang J, Gao HX, Putterman C, Koss MN, Stohl W, Jacob CO. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol 2009, 182:2532-2541. 10.4049/jimmunol.0802948, 2790862, 19201910.
11. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008, 127:385-393. 10.1016/j.clim.2008.01.019, 18373953.
12. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000, 9:589-593. 10.1191/096120300678828703, 11035433.
13. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy-Berard N. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009, 10:778-785.
14. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, Kim SH, Park HS, Suh CH. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007, 27:461-466. 10.1007/s10875-007-9104-0, 17587156.
15. Stuart RA, Littlewood AJ, Maddison PJ, Hall ND. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995, 13:17-22.
16. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000, 18:565-570.
17. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991, 147:117-123.
18. Lai Kwan Lam Q, King Hung Ko O, Zheng BJ, Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci USA 2008, 105:14993-14998. 10.1073/pnas.0806044105, 2567481, 18820032.
19. Stojanovic I, Cvjeticanin T, Lazaroski S, Stosic-Grujicic S, Miljkovic D. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology 2009, 126:74-83. 10.1111/j.1365-2567.2008.02879.x, 2632697, 18624729.
20. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004, 31:268-273.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
22. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996, 35:248-254. 10.1093/rheumatology/35.3.248, 8620300.
23. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.
24. Ibanez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003, 30:1977-1982.
25. Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005, 32:824-827.
26. Lina C, Conghua W, Nan L, Ping Z. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol 2011, 31:596-605. 10.1007/s10875-011-9542-6, 21562776.
27. Prado C, de Paz B, Gomez J, Lopez P, Rodriguez-Carrio J, Suarez A. Glucocorticoids enhance Th17/Th1 imbalance and signal transducer and activator of transcription 3 expression in systemic lupus erythematosus patients. Rheumatology (Oxford) 2011, 50:1794-1801. 10.1093/rheumatology/ker227, 21750002.
28. Ma J, Yu J, Tao X, Cai L, Wang J, Zheng SG. The imbalance between regulatory and IL-17-secreting CD4+ T cells in lupus patients. Clin Rheumatol 2010, 29:1251-1258. 10.1007/s10067-010-1510-7, 20563617.
29. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010, 30:80-89. 10.1007/s10875-009-9345-1, 19936899.
30. Kang EH, Lee YJ, Hyon JY, Yun PY, Song YW. Salivary cytokine profiles in primary Sjogren's syndrome differ from those in non-Sjogren sicca in terms of TNF-alpha levels and Th-1/Th-2 ratios. Clin Exp Rheumatol 2011, 29:970-976.
31. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, Lukic ML. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res 2012, 46:1421-1426. 10.1016/j.jpsychires.2012.08.016, 22974591.
32. Sousa GM, Oliveira IS, Andrade LJ, Sousa-Atta ML, Parana R, Atta AM. Serum levels of Th17 associated cytokines in chronic hepatitis C virus infection. Cytokine 2012, 60:138-142. 10.1016/j.cyto.2012.06.003, 22748467.
33. Cheng F, Guo Z, Xu H, Yan D, Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009, 68:604-606. 10.1136/ard.2008.097089, 19286907.
34. Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, Wu GC, Su H, Pan FM, Li WX, Li LH, Chen GP, Ye DQ. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010, 37:81-85. 10.1007/s11033-009-9533-3, 19347604.
35. O'Connor RA, Prendergast CT, Sabatos CA, Lau CW, Leech MD, Wraith DC, Anderton SM. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2008, 181:3750-3754. 2619513, 18768826.
36. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999, 5:101-104.
37. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007, 13:1173-1175. 10.1038/nm1651, 17828272.
38. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748. 10.1038/nature01355, 12610626.
39. Meyers JA, Mangini AJ, Nagai T, Roff CF, Sehy D, van Seventer GA, van Seventer JM. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Cytokine 2006, 35:235-246. 10.1016/j.cyto.2006.09.001, 17052915.
40. Shah K, Lee WW, Lee SH, Kim SH, Kang SW, Craft J, Kang I. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R53. 10.1186/ar2964, 2888202, 20334681.
41. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700. 10.1136/gutjnl-2011-301668, 22595313.
42. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Mpofu S. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013, 72:863-869. 10.1136/annrheumdis-2012-201601, 22730366.
43. Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a randomised, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013, 168:412-421. 10.1111/bjd.12110, 23106107.
44. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939. 10.1002/art.27334, 20131262.
45. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366:1190-1199. 10.1056/NEJMoa1109997, 22455413.
46. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366:1181-1189. 10.1056/NEJMoa1109017, 22455412.
47. Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, Nishihara M, Iwakura Y, Hirano T. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008, 29:628-636. 10.1016/j.immuni.2008.07.018, 18848474.
48. Dong G, Ye R, Shi W, Liu S, Wang T, Yang X, Yang N, Yu X. IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J (Engl) 2003, 116:543-548.
49. Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, Mills KH. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J Immunol 2009, 183:1715-1723. 10.4049/jimmunol.0803851, 19570828.
50. Stojanovic I, Cvjetićanin T, Lazaroski S, Stosić-Grujicic S, Miljkovic D. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology 2009, 126:74-83. 10.1111/j.1365-2567.2008.02879.x, 2632697, 18624729.
51. Zhou X, Xia Z, Lan Q, Wang J, Su W, Han YP, Fan H, Liu Z, Stohl W, Zheng SG. BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One 2011, 6:e23629. 10.1371/journal.pone.0023629, 3163640, 21897850.
52. Barbosa RR, Silva SP, Silva SL, Melo AC, Pedro E, Barbosa MP, Pereira-Santos MC, Victorino RM, Sousa AE. Primary B-cell deficiencies reveal a link between human IL-17-producing CD4 T-cell homeostasis and B-cell differentiation. PLoS One 2011, 6:e22848. 10.1371/journal.pone.0022848, 3149619, 21826211.